Daily Digest
Daily Digest
Pomegra Startups
Funding rounds, valuations, acquisitions, and IPOs - daily coverage of the companies shaping the private markets
Outer Bio (US) — Lady Gaga co-founded biotech exits stealth with $23M, keeping donated human skin alive for four weeks to train AI models on tissue aging and screen 750M compounds annually for skin longevity.
AusperBio (US) closes a $120M Series C bringing total raised to $360M — the San Jose-based biotech is advancing its lead hepatitis B therapy AHB-137 into a Phase 3 registrational trial toward a potential functional cure for chronic HBV.
LifeMine Therapeutics (US) closes $188M Series E backed by Bezos Expeditions, Gates Frontier, and RA Capital to advance LIFE-001, a fungi-derived drug designed to replace toxic calcineurin inhibitors used to prevent organ rejection.
Bridge to Life (US) closes $110M Series C led by Soleus Capital to commercialize VitaSmart, the only FDA-cleared hypothermic oxygenated perfusion system for liver transplants.
Seattle biotech InduPro closes a $77M Series B led by The Column Group, dosing its first patient in a Phase 1 trial of IDP-001, an antibody-drug conjugate targeting advanced non-small cell lung cancer and other solid tumors.
US biotech EpiCrispr Biotechnologies closes a $90M oversubscribed Series C led by Octagon Capital and Janus Henderson to advance its lead epigenetic gene therapy toward pivotal studies in rare muscle disease FSHD.
Toronto AI biotech Biossil exits stealth with $70M co-led by Founders Fund and OpenAI to acquire and rescue failed drug candidates using large language models, with several molecules already in clinical trials.
Boston biotech Beeline Medicines raises a $126M Series A extension backed by Bain Capital and Bristol-Myers Squibb to advance precision therapies for autoimmune and inflammatory diseases.
Swiss biotech Vaderis Therapeutics closes an oversubscribed $152M Series B led by Goldman Sachs Life Sciences to fund a global Phase 3 trial of engasertib, a potential first-ever approved treatment for rare vascular disorder HHT.
Immunology biotech Boulevard Bio exits stealth with $65M from Deerfield Management to advance a pipeline of multi-specific antibodies for autoimmune diseases including IgA nephropathy.
Canadian biotech Biossil exits stealth with $70M to repurpose previously failed drug compounds for new therapeutic indications.
Pomegra